New Therapeutic Options for Fusariosis: A Patent Review (2008-2023)

Izadora Dillis Faccin1, Túlio Máximo Salomé1, Gleyce Hellen de Almeida de Souza1

  • 1Health Sciences Research Laboratory, Universidade Federal of Grande Dourados, 79804-970 Dourados, Brazil.

Insights

Antifungal resistance necessitates new treatments for Fusariosis. Patent analysis reveals innovation in drug delivery, gene expression, and novel compounds for human Fusarium infections.

Area of Science:

  • Mycology
  • Infectious Diseases
  • Pharmaceutical Sciences

Background:

  • Fusariosis, caused by *Fusarium* species, affects plants and humans.
  • Current treatments (azoles, polyenes) face rising antifungal resistance.
  • Novel therapeutic strategies are crucial for managing Fusariosis.

Purpose of the Study:

  • To review patents for Fusariosis treatments over the last 15 years (up to June 2023).
  • To identify trends in therapeutic approaches and mechanisms of action.
  • To assess the landscape of innovation in combating *Fusarium* infections.

Main Methods:

  • Systematic patent search using International Patent Classification and Cooperative Patent Classification.
  • Bibliographic search in PubMed for scientific articles.
  • Categorization of patents by identification code, publication date, application type, and mechanism.

Main Results:

  • 318 patents related to Fusariosis treatment were identified.
  • 21 patents specifically targeted human Fusarium infections.
  • Key innovation areas include drug delivery, gene expression, immunotherapy, engineered drugs, and novel compounds.
  • Peak patent activity observed in 2014 and 2018.

Conclusions:

  • The patent landscape indicates active research into new Fusariosis therapies.
  • Diverse mechanisms, including advanced drug delivery and immunotherapy, are being explored.
  • Continued innovation is essential to address the challenge of antifungal resistance in Fusariosis treatment.

Related Concept Videos

Fungal Phylum Microsporidia01:28

Fungal Phylum Microsporidia

Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...
128
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
375
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
4.8K